Skip to Content

Treatment Options for FLT3 mutant acute myeloid leukemia

AML is a biologically heterogeneous disease, with many different karyotype mutations and antigens characterizing patients with this aggressive malignancy. One of these mutants is FLT3 mutant AML. It is mainly observed in younger patients with acute myeloid leukemia and is an independent predictor of shorter disease-free and overall survival.

In this MEDtalk, Dr Eunice Wang from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, presents treatment options for FLT3 mutant acute myeloid leukemia for both fit and unfit patients and patients with relapsed/refractory AML. Dr Eunice Wang also gives her perspective on doublet vs triplet therapy.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top